Quick Answer
Camp4 Therapeutics Corp reported R&D Expense of $38.20 million for fiscal year 2025.
Camp4 Therapeutics Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $38.20M | -1.6% |
| 2024 | $38.82M | -4.4% |
| 2023 | $40.62M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.36M | -3.6% | -9.5% |
| June 30, 2025 | $10.34M | +10.2% | +1.9% |
| March 31, 2025 | $10.15M | +4.2% | +4.6% |
| September 30, 2024 | $9.70M | -1.2% | +3.3% |
| June 30, 2024 | $9.39M | — | -3.6% |
| March 31, 2024 | $9.74M | — | -0.8% |
| September 30, 2023 | $9.82M | — | — |
- Camp4 Therapeutics Corp showed a decrease of -1.6% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Camp4 Therapeutics Corp’s r&d expense has declined by 5.9% (from $40.62 million to $38.20 million).
- The most recent figure is from Camp4 Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: